Pradaxa is a non-vitamin K oral anticoagulant (NOAC) and the only direct thrombin inhibitor for the prevention of stroke in patients with atrial fibrillation.
The product website for Pradaxa was developed for healthcare professionals to provide information on clinical trials, patient types, indications and dosing, as well as the latest news and guidance on how to use the dabigatran-specific reversal agent, Praxbind, in emergency situations.
The ESO (European Stroke Organisation) is a non-profit organisation of stroke researchers and physicians, national and regional stroke societies, and other affiliated organisations. The aim of the ESO is to reduce the incidence and impact of stroke by influencing the way stroke is viewed and treated.
The website contains information about becoming a member, upcoming ESO conferences/events, educational resources, guidelines, and stroke information.
The WSO (World Stroke Organization) is an international organization focused on reducing the global burden of stroke through prevention, treatment and long-term care. The WSO was established in 2006 following the merger of the International Stroke Society and the World Stroke Federation.
The website contains information regarding membership, upcoming meetings, educational resources, and news and publications.
The WSA is the elearning platform of the World Stroke Organization for healthcare professionals and is overseen by a team of international stroke experts. Registered professionals can access information on stroke care, webcasts from congresses, podcasts, elearning modules and online quizzes.
The Boehringer Ingelheim cardiovascular site provides information for all its cardiovascular indications. The website contains treatment information on stroke prevention in atrial fibrillation, acute ischaemic stroke, hypertension, reversal of anti-coagulation, deep vein thrombosis /pulmonary embolism, and myocardial infarction.